))
Ep 3 - A Conversation with Sue Dillon (Aro Biotherapeutics)
Manage episode 417193478 series 3478712
Content provided by Scheer Partners. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Scheer Partners or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
On this episode of BioBlast, Devin Zitelman interviews Susan Dillon, PhD the president and CEO of Aro Biotherapeutics.
Sue Dillon is a co-founder of Aro Biotherapeutics, focused on Centyrins, a unique protein platform designed to enable optimized delivery of multiple drug payloads including nucleic acid and genetic therapeutics for diseases with high unmet need.
Sue earned her Ph.D. in Microbiology and Immunology from Thomas Jefferson University, Philadelphia and completed an NIH-sponsored postdoctoral fellowship in Immunology at Duke University. Sue has published over 50 scientific articles and is inventor on six issued patents.
In 2007, Sue was awarded the Distinguished Alumni Award from Thomas Jefferson University and in 2013 Sue was selected by FierceBiotech as one of the “Top Women in Biotech.”
20 episodes
Share
